DOCSLIB.ORG

Active Labelers Run Date : Aug 26, 2021

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Active Labelers Run Date : Aug 26, 2021 Labeler ID Labeler Name Contract Begin Date Contract End Date 00002 ELI LILLY AND COMPANY 01/01/1991 01/01/3000 00003 E.R. SQUIBB & SONS, LLC. 01/01/1991 01/01/3000 00004 GENENTECH, INC. 01/01/1991 01/01/3000 00006 MERCK SHARP & DOHME CORP. 01/01/1991 01/01/3000 00007 GLAXOSMITHKLINE LLC 01/01/1991 01/01/3000 00008 WYETH PHARMACEUTICALS LLC, 01/01/1991 01/01/3000 00009 PHARMACIA AND UPJOHN COMPANY LLC 01/01/1991 01/01/3000 00013 PFIZER LABORATORIES DIV PFIZER INC 01/01/1991 01/01/3000 00014 PFIZER, INC 01/01/1991 01/01/3000 00015 MEAD JOHNSON AND COMPANY 01/01/1991 01/01/3000 00023 ALLERGAN INC 01/01/1991 01/01/3000 00024 SANOFI-AVENTIS, US LLC 01/01/1991 01/01/3000 00025 PFIZER LABORATORIES DIV PFIZER INC 01/01/1991 01/01/3000 00026 BAYER HEALTHCARE LLC 01/01/1991 01/01/3000 00032 ABBVIE INC. 01/01/1991 01/01/3000 00037 MEDA PHARMACEUTICALS, INC. 01/01/1991 01/01/3000 00039 SANOFI-AVENTIS, US LLC 01/01/1991 01/01/3000 00046 WYETH PHARMACEUTICALS INC. 01/01/1991 01/01/3000 00049 ROERIG 01/01/1991 01/01/3000 00051 ABBVIE INC 10/01/1997 01/01/3000 00052 MERCK SHARP & DOHME CORP 01/01/1991 01/01/3000 00053 CSL BEHRING L.L.C. 01/01/1991 01/01/3000 00054 HIKMA PHARMACEUTICALS USA INC. 01/01/1991 01/01/3000 00056 BRISTOL-MYERS SQUIBB PHARMA CO. 01/01/1991 01/01/3000 00065 ALCON LABORATORIES, INC. 01/01/1991 01/01/3000 00068 SANOFI-AVENTIS U.S. LLC 01/01/1991 01/01/3000 00069 PFIZER LABORATORIES DIV PFIZER INC 01/01/1991 01/01/3000 00070 AVENTIS PHARMACEUTCALS 01/01/1991 01/01/3000 00071 PARKE-DAVIS DIV OF PFIZER 01/01/1991 01/01/3000 00074 ABBVIE INC 01/01/1991 01/01/3000 00075 SANOFI-AVENTIS U.S. LLC 01/01/1991 01/01/3000 00078 NOVARTIS PHARMACEUTICALS CORPORATION 01/01/1991 01/01/3000 00085 MERCK SHARP & DOHME CORP. 01/01/1991 01/01/3000 00087 BRISTOL-MYERS SQUIBB COMPANY 01/01/1991 01/01/3000 00088 SANOFI-AVENTIS U.S.LLC 01/01/1991 01/01/3000 00093 TEVA PHARMACEUTICALS USA, INC. 01/01/1991 01/01/3000 00095 BAUSCH HEALTH US, LLC 10/01/1991 01/01/3000 ©2021 Magellan Health, Inc. All Rights Reserved. Terms of Use / Privacy Policy / Disclaimer / Nondiscrimination & Languages Active Labelers Run Date : Aug 26, 2021 Labeler ID Labeler Name Contract Begin Date Contract End Date 00096 PERSON & COVEY, INC. 04/01/1999 01/01/3000 00113 L. PERRIGO COMPANY 04/30/2003 01/01/3000 00115 AMNEAL PHARMACEUTICALS OF NEW YORK LLC 01/01/1991 01/01/3000 00116 XTTRIUM LABORATORIES, INC. 08/17/2001 01/01/3000 00121 PHARMACEUTICAL ASSOCIATES, INC. 01/01/1991 01/01/3000 00131 UCB, INC. 01/01/1991 01/01/3000 00132 C B FLEET COMPANY INC 01/01/1991 01/01/3000 00143 HIKMA PHARMACEUTICALS USA INC. 01/01/1991 01/01/3000 00145 STIEFEL LABORATORIES, INC, 01/01/1991 01/01/3000 00168 E FOUGERA AND CO. 01/01/1991 01/01/3000 00169 NOVO NORDISK, INC. 01/01/1991 01/01/3000 00172 TEVA PHARMACEUTICALS USA, INC 01/01/1991 01/01/3000 00173 GLAXOSMITHKLINE 01/01/1991 01/01/3000 00178 MISSION PHARMACAL COMPANY 01/01/1991 01/01/3000 00185 EON LABS, INC. 01/01/1991 01/01/3000 00186 ASTRAZENECA PHARMACEUTICALS LP 01/01/1991 01/01/3000 00187 BAUSCH HEALTH US, LLC. 01/01/1991 01/01/3000 00192 BAYER CORPORATION PHARMACEUTICAL DIV. 01/01/1991 01/01/3000 00206 WYETH PHARMACEUTICALS LLC, 01/01/1991 01/01/3000 00224 KONSYL PHARMACEUTICALS, INC. 01/01/1992 01/01/3000 00225 B. F. ASCHER AND COMPANY, INC. 01/01/1991 01/01/3000 00228 ACTAVIS PHARMA, INC. 01/01/1991 01/01/3000 00245 UPSHER-SMITH LABORATORIES, INC. 01/01/1991 01/01/3000 00254 PAR PHARMACEUTICAL INC. 09/28/2018 01/01/3000 00259 MERZ PHARMACEUTICALS 01/01/1991 01/01/3000 00264 B. BRAUN MEDICAL INC. 01/01/1991 01/01/3000 00281 SAVAGE LABORATORIES 01/01/1991 01/01/3000 00299 GALDERMA LABORATORIES, L.P. 01/01/1991 01/01/3000 00310 ASTRAZENECA PHARMACEUTICALS LP 01/01/1991 01/01/3000 00338 BAXTER HEALTHCARE CORPORATION 01/01/1991 01/01/3000 00378 MYLAN PHARMACEUTICALS, INC. 01/01/1991 01/01/3000 00406 SPEC GX, LLC 10/01/1991 01/01/3000 00407 GE HEALTHCARE, INC. 07/05/2011 01/01/3000 00409 HOSPIRA, INC. 10/28/2004 01/01/3000 00430 ALLERGAN, INC. 01/01/1998 01/01/3000 00456 ALLERGAN, INC. 01/01/1991 01/01/3000 00469 ASTELLAS PHARMA US, INC. 01/01/1991 01/01/3000 ©2021 Magellan Health, Inc. All Rights Reserved. Terms of Use / Privacy Policy / Disclaimer / Nondiscrimination & Languages Active Labelers Run Date : Aug 26, 2021 Labeler ID Labeler Name Contract Begin Date Contract End Date 00472 ACTAVIS PHARMA, INC. 01/01/1991 01/01/3000 00485 EDWARDS PHARMACEUTICALS, INC. 01/01/1991 01/01/3000 00486 BEACH PHARMACEUTICALS 01/01/1991 01/01/3000 00487 NEPHRON PHARMACEUTICALS CORPORATION 04/01/1992 01/01/3000 00517 AMERICAN REGENT, INC. 10/01/1991 01/01/3000 00527 LANNETT COMPANY, INC. 07/01/1994 01/01/3000 00536 RUGBY LABORATORIES 01/01/1991 01/01/3000 00548 AMPHASTAR PHARMACEUTICALS, INC. 10/22/2012 01/01/3000 00555 TEVA PHARMACEUTICALS USA, INC 01/01/1991 01/01/3000 00562 KEDRION MELVILLE, INC. 01/18/2013 01/01/3000 00574 PADDOCK LABORATORIES, LLC. 01/01/1991 01/01/3000 00575 TEVA PHARMACEUTICALS USA, INC 10/01/1991 01/01/3000 00591 ACTAVIS PHARMA, INC. 03/29/2001 01/01/3000 00597 BOEHRINGER INGELHEIM PHARMACEUTICALS 01/01/1991 01/01/3000 00603 PAR PHARMACEUTICAL 01/01/1991 01/01/3000 00641 HIKMA PHARMACEUTICALS USA INC. 01/01/1991 01/01/3000 00642 EXELTIS USA, INC. 01/01/1991 01/01/3000 00662 PFIZER-ROERIG 01/01/1991 01/01/3000 00663 PFIZER, INC 01/01/1991 01/01/3000 00682 MARNEL PHARMACEUTICALS, LLC 01/01/1991 01/01/3000 00703 TEVA PARENTERAL MEDICINES INC 07/01/1992 01/01/3000 00713 COSETTE PHARMACEUTICALS, INC. 07/01/1991 01/01/3000 00777 DISTA PRODUCTS COMPANY 01/01/1991 01/01/3000 00781 SANDOZ 01/01/1991 01/01/3000 00813 PHARMICS INC. 01/01/1991 01/01/3000 00832 UPSHER-SMITH LABORATORIES, LLC. 01/01/1991 01/01/3000 00884 PEDINOL PHARMACAL INC 01/01/1991 01/01/3000 00904 MAJOR PHARMACEUTICALS 01/01/1991 01/01/3000 00905 PFIZER, INC 01/01/1991 01/01/3000 00941 BAXTER HEALTHCARE CORPORATION 04/01/2010 01/01/3000 00944 BAXALTA US INC. 01/01/1991 01/01/3000 00955 WINTHROP U.S. 01/01/1996 01/01/3000 00990 ICU MEDICAL INC. 07/12/2018 01/01/3000 00995 PFIZER, INC 01/01/1991 01/01/3000 00998 ALCON LABORATORIES, INC. 01/01/1991 01/01/3000 10019 BAXTER HEALTHCARE CORPORATION 06/28/2001 01/01/3000 10094 AQUESTIVE THERAPEUTICS 12/05/2018 01/01/3000 ©2021 Magellan Health, Inc. All Rights Reserved. Terms of Use / Privacy Policy / Disclaimer / Nondiscrimination & Languages Active Labelers Run Date : Aug 26, 2021 Labeler ID Labeler Name Contract Begin Date Contract End Date 10122 CHIESI USA, INC. 04/26/2005 01/01/3000 10144 ACORDA THERAPEUTICS, INC. 05/27/2005 01/01/3000 10147 PATRIOT PHARMACEUTICALS, LLC. 01/13/2005 01/01/3000 10148 COTHERIX, INC. 09/06/2018 01/01/3000 10337 PHARMADERM (DIVISION OF FOUGERA PHARMA) 04/16/2002 01/01/3000 10370 PAR PHARMACEUTICALS, INC. 05/14/2007 01/01/3000 10454 SOLSTICE NEUROSCIENCES, LLC. 10/18/2005 01/01/3000 10542 HILLESTAD PHARMACEUTICALS USA 04/01/1994 01/01/3000 10572 AFFORDABLE PHARMACEUTICALS, LLC 11/01/2004 01/01/3000 10599 INTERSECT ENT, INC. 02/12/2018 01/01/3000 10631 SUN PHARMACEUTICALS INDUSTRIES, INC. 07/20/2005 01/01/3000 10702 KVK-TECH, INC. 10/10/2006 01/01/3000 10885 GALEN US INCORPORATED 11/22/2013 01/01/3000 10922 INTENDIS, INC. 08/01/2005 01/01/3000 11042 MIDDLEBROOK PHARMACEUTICALS, INC. 08/22/2005 01/01/3000 11527 SHEFFIELD PHARMACEUTICALS 04/28/2020 01/01/3000 11534 SUNRISE PHARMACEUTICAL, INC. 10/12/2015 01/01/3000 11980 ALLERGAN INC 01/01/1991 01/01/3000 11994 LANTHEUS MEDICAL IMAGING, INC. 10/06/2010 01/01/3000 12496 INDIVOR INC. 01/01/1994 01/01/3000 12830 R.A. MCNEIL COMPANY 01/01/1991 01/01/3000 13107 AUROBINDO PHARMA USA, INC. 06/02/2005 01/01/3000 13517 E5 PHARMA, LLC 01/30/2017 01/01/3000 13533 GRIFOLS USA, LLC 07/21/2005 01/01/3000 13548 BAUSCH HEALTH US, LLC 04/01/2006 01/01/3000 13668 TORRENT PHARMACEUTICALS LIMITED 07/02/2007 01/01/3000 13811 TRIGEN LABORATORIES, LLC 01/09/2006 01/01/3000 13845 PARSOLEX GMP CENTER, INC. 04/30/2009 01/01/3000 13913 ASSERTIO THERAPEUTICS, INC. 07/27/2005 01/01/3000 13925 SETON PHARMACEUTICALS, LLC 11/18/2008 01/01/3000 14539 HERITAGE PHARMACEUTICALS, INC. 07/29/2019 01/01/3000 14789 NEXUS PHARMACEUTICALS, INC. 01/09/2018 01/01/3000 15054 IPSEN BIOPHARMACEUTICALS 01/26/2006 01/01/3000 15370 CARWIN PHARMACEUTICAL ASSOCIATES, LLC. 06/16/2006 01/01/3000 15584 GILEAD SCIENCES, LLC. 07/01/2006 01/01/3000 16252 ACTAVIS PHARMA, INC.
Recommended publications
  • Biotech Investing 2020

    Biotech Investing 2020

    BIOTECH INVESTING 2020 Bill Cara www.billcara.com [email protected] 647-868-6013 JULY 20, 2020 A. Report Overview This Greenfield Capital (billcara.com) report on the Biotechnology industry is written by a registered investment consultant & portfolio manager, not by a scientist. Our objective is to provide education and information to investors who lack the tools to trade successfully in an industry made vitally important to the world by the coronavirus pandemic of 2020. If we want to live through this pandemic -- and future ones -- where it is possible that hundreds of millions of us could perish because of the lack of diagnostics, vaccines, and therapeutics, then as investors we should be keenly interested in the Biotech industry. News reports state that in just six and a half months, COVID-19, initially called SARS- CoV-2, has killed more people than the number of Americans who die each year from opioid overdose (46,000), traffic accidents (36,500), and gun violence (40,000) combined. But, currently, there is no vaccine for COVID-19, and the treatment options for patients with severe or life-threatening symptoms are limited. As the world struggles to contain the deadly virus, there are, fortunately, over 140 coronavirus vaccines in development. News is breaking every day. At the same time, however, many individuals who are trading in Biotech stocks remain woefully uninformed and are speculating wildly. Some Biotech stocks that have appreciated 100% or more in a few months on hopefulness may have trouble sustaining gains beyond the news peak. Still, for investors who study this industry, there are opportunities right now to buy Biotech stocks that will grow in price well into the future.
  • The Top 100 November, 2016 a List of Stocks Topping Our Custom 'Torpedo’ Screen

    The Top 100 November, 2016 a List of Stocks Topping Our Custom 'Torpedo’ Screen

    The Top 100 November, 2016 A list of stocks topping our custom 'torpedo’ screen. Updated monthly. GPRO GoPro, Inc. Class A Consumer Discretionary TSLA Tesla Motors, Inc. Consumer Discretionary UA Under Armour, Inc. Class A Consumer Discretionary CRC California Resources Corp Energy CRZO Carrizo Oil & Gas, Inc. Energy CWEI Clayton Williams Energy, Inc. Energy FANG Diamondback Energy, Inc. Energy GST Gastar Exploration, Inc. Energy MPLX MPLX LP Energy RSPP RSP Permian, Inc. Energy SLCA U.S. Silica Holdings, Inc. Energy AAC AAC Holdings, Inc. Health Care ABEO Abeona Therapeutics, Inc. Health Care ACAD ACADIA Pharmaceuticals Inc. Health Care ADMP Adamis Pharmaceuticals Corporation Health Care ADMS Adamas Pharmaceuticals, Inc. Health Care ADXS Advaxis, Inc. Health Care AIMT Aimmune Therapeutics Inc Health Care AKBA Akebia Therapeutics, Inc. Health Care ALDR Alder Biopharmaceuticals, Inc. Health Care ARDM Aradigm Corporation Health Care ARDX Ardelyx, Inc. Health Care ARLZ Aralez Pharmaceuticals Inc. Health Care ATRA Atara Biotherapeutics Inc Health Care BCRX BioCryst Pharmaceuticals, Inc. Health Care BLUE bluebird bio, Inc. Health Care CARA Cara Therapeutics Inc Health Care CDNA CareDx, Inc. Health Care CEMP Cempra, Inc. Health Care CERS Cerus Corporation Health Care CFMS ConforMIS Inc Health Care CLVS Clovis Oncology, Inc. Health Care COLL Collegium Pharmaceutical, Inc. Health Care CORI Corium International, Inc. Health Care CRMD CorMedix Inc. Health Care CSU Capital Senior Living Corporation Health Care DERM Dermira Inc Health Care DVAX Dynavax Technologies Corporation Health Care DXCM DexCom, Inc. Health Care EPZM Epizyme, Inc. Health Care FOLD Amicus Therapeutics, Inc. Health Care HRTX Heron Therapeutics Inc Health Care ICPT Intercept Pharmaceuticals, Inc.
  • Infectious Diseases

    Infectious Diseases

    2013 MEDICINES IN DEVELOPMENT REPORT Infectious Diseases A Report on Diseases Caused by Bacteria, Viruses, Fungi and Parasites PRESENTED BY AMERICA’S BIOPHARMACEUTICAL RESEARCH COMPANIES Biopharmaceutical Research Evolves Against Infectious Diseases with Nearly 400 Medicines and Vaccines in Testing Throughout history, infectious diseases hepatitis C that inhibits the enzyme have taken a devastating toll on the lives essential for viral replication. and well-being of people around the • An anti-malarial drug that has shown Medicines in Development world. Caused when pathogens such activity against Plasmodium falci- For Infectious Diseases as bacteria or viruses enter a body and parum malaria which is resistant to multiply, infectious diseases were the current treatments. Application leading cause of death in the United Submitted States until the 1920s. Today, vaccines • A potential new antibiotic to treat methicillin-resistant Staphylococcus Phase III and infectious disease treatments have proven to be effective treatments in aureus (MRSA). Phase II many cases, but infectious diseases still • A novel treatment that works by Phase I pose a very serious threat to patients. blocking the ability of the smallpox Recently, some infectious pathogens, virus to spread to other cells, thus 226 such as pseudomonas bacteria, have preventing it from causing disease. become resistant to available treatments. Infectious diseases may never be fully Diseases once considered conquered, eradicated. However, new knowledge, such as tuberculosis, have reemerged new technologies, and the continuing as a growing health threat. commitment of America’s biopharma- America’s biopharmaceutical research ceutical research companies can help companies are developing 394 medicines meet the continuing—and ever-changing and vaccines to combat the many threats —threat from infectious diseases.
  • 05/01/02 Louisiana Medicaid Management

    05/01/02 Louisiana Medicaid Management

    APPENDIX C 05/01/02 LOUISIANA MEDICAID MANAGEMENT INFORMATION SYSTEM PAGE 1 DEPT OF HEALTH AND HOSPITALS - BUREAU OF HEALTH SERVICES FINANCING LOUISIANA MEDICAID PHARMACY BENEFITS MANAGEMENT UNIT ONLY THESE COMPANIES PRODUCTS ARE COVERED AND ONLY THOSE DOSAGE FORMS LISTED IN APPENDIX A. MEDICAID DRUG FEDERAL REBATE PARTICIPATING PHARMACEUTICAL COMPANIES LABELER PHARMACEUTICAL COMPANY EFFECTIVE END DATE CODE DATE 00002 ELI LILLY & CO 04/01/91 00003 E.R.SQUIBB & SONS,INC 04/01/91 00004 HOFFMAN-LA ROCHE,INC 04/01/91 00005 LEDERLE LABORATORIES AMERICAN CYANAMID 04/01/91 00006 MERCK SHARP & DOHME 04/01/91 00007 SMITHKLINE BEECHAM CORPORATION 04/01/91 00008 WYETH LABORATORIES 04/01/91 00009 THE UPJOHN COMPANY 04/01/91 00011 BECTON DICKINSON MICROBIOLOGY SYSTEMS 10/01/91 07/01/98 00013 ADRIA LABORATORIES DIV.OF ERBAMONT,INC 04/01/91 00014 G.D.SEARLE & CO 04/01/91 01/01/01 00015 MEAD JOHNSON & COMPANY 04/01/91 00016 KABI PHARMACIA 04/01/91 00021 REED & CARNRICK 10/01/96 01/01/97 00023 ALLERGAN,INC 04/01/91 00024 WINTHROP PHARMACEUTICALS 04/01/91 00025 G.D.SEARLE & CO 04/01/91 00026 MILES INC.,PHARMACEUTICAL DIVISION 04/01/91 00028 GEIGY PHARMACEUTICALS 04/01/91 00029 SMITHKLINE BEECHAM CORPORATION 04/01/91 00031 ROBINS,A.H. 04/01/91 00032 SOLVAY PHARMACEUTICALS 04/01/91 00033 SYNTEX 04/01/91 00034 THE PURDUE FREDERICK COMPANY 04/01/91 00037 CARTER-WALLACE,INC 04/01/91 00038 STUART PHARMACEUTICALS,ICI AMERICAS INC 04/01/91 07/01/01 00039 HOECHST-ROUSSEL PHARMACEUTICALS INC 04/01/91 00043 SANDOZ CONSUMER CORPORATION 04/01/91 00044 KNOLL PHARMACEUTICALS
  • United States Court of Appeals for The

    United States Court of Appeals for The

    Case 14-4353, Document 100-1, 05/16/2016, 1772362, Page1 of 37 14‐4353‐cv Apotex Inc., et al., v. Acorda Therapeutics, Inc. UNITED STATES COURT OF APPEALS FOR THE SECOND CIRCUIT August Term, 2015 (Argued: November 12, 2015 Decided: May 16, 2016) Docket No. 14‐4353‐cv ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐x APOTEX INC., et al., Plaintiffs‐Appellants, ‐ v.‐ ACORDA THERAPEUTICS, INC., Defendant‐Appellee. ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐x Before: JACOBS, LIVINGSTON and DRONEY, Circuit Judges. This appeal concerns two distinct questions: the circumstances under which the filing of a citizen petition with the Food and Drug Administration provides grounds for an antitrust claim, and the scope of false advertising Case 14-4353, Document 100-1, 05/16/2016, 1772362, Page2 of 37 liability under the Lanham Act. Plaintiffs Apotex Incorporated and Apotex Corporation appeal from the judgment of the United States District Court for the Southern District of New York (Swain, J.) that granted defendant Acorda Therapeutics, Inc.’s motion to dismiss plaintiffs’ Sherman Act claim and that granted summary judgment in favor of defendant on the Lanham Act claims (Torres, J.). Because each of these conclusions was sound, we affirm. KEITH D. PARR (with Joseph N. Froehlich, Scott B. Feder, Hugh S. Balsam, James T. Peterka, and Andy J. Miller on the brief), Locke Lord LLP, Chicago, Illinois, for Appellants Apotex Incorporated & Apotex Corporation. JOHN W. NIELDS, JR. (with Jason C. Raofield and Colin P. Watson on the brief), Covington & Burling LLP, Washington, D.C. for Appellee Acorda Therapeutics, Inc. DENNIS JACOBS, Circuit Judge: The parties are rival manufacturers of tizanidine, a drug for treating spasticity.
  • March 31, 2021

    March 31, 2021

    Units Cost Market Value US Equity Index Fund US Equities 95.82% Domestic Common Stocks 10X GENOMICS INC 126 10,868 24,673 1LIFE HEALTHCARE INC 145 6,151 4,794 2U INC 101 5,298 4,209 3D SYSTEMS CORP 230 5,461 9,193 3M CO 1,076 182,991 213,726 8X8 INC 156 2,204 4,331 A O SMITH CORP 401 17,703 28,896 A10 NETWORKS INC 58 350 653 AAON INC 82 3,107 5,132 AARON'S CO INC/THE 43 636 1,376 ABBOTT LABORATORIES 3,285 156,764 380,830 ABBVIE INC 3,463 250,453 390,072 ABERCROMBIE & FITCH CO 88 2,520 4,086 ABIOMED INC 81 6,829 25,281 ABM INDUSTRIES INC 90 2,579 3,992 ACACIA RESEARCH CORP 105 1,779 710 ACADIA HEALTHCARE CO INC 158 8,583 9,915 ACADIA PHARMACEUTICALS INC 194 6,132 4,732 ACADIA REALTY TRUST 47 1,418 1,032 ACCELERATE DIAGNOSTICS INC 80 1,788 645 ACCELERON PHARMA INC 70 2,571 8,784 ACCO BRANDS CORP 187 1,685 1,614 ACCURAY INC 64 483 289 ACI WORLDWIDE INC 166 3,338 6,165 ACTIVISION BLIZZARD INC 1,394 52,457 133,043 ACUITY BRANDS INC 77 13,124 14,401 ACUSHNET HOLDINGS CORP 130 2,487 6,422 ADAPTHEALTH CORP 394 14,628 10,800 ADAPTIVE BIOTECHNOLOGIES CORP 245 11,342 10,011 ADOBE INC 891 82,407 521,805 ADT INC 117 716 1,262 ADTALEM GLOBAL EDUCATION INC 99 4,475 3,528 ADTRAN INC 102 2,202 2,106 ADVANCE AUTO PARTS INC 36 6,442 7,385 ADVANCED DRAINAGE SYSTEMS INC 116 3,153 13,522 ADVANCED ENERGY INDUSTRIES INC 64 1,704 7,213 ADVANCED MICRO DEVICES INC 2,228 43,435 209,276 ADVERUM BIOTECHNOLOGIES INC 439 8,321 1,537 AECOM 283 12,113 17,920 AERIE PHARMACEUTICALS INC 78 2,709 1,249 AERSALE CORP 2,551 30,599 31,785 AES CORP/THE 1,294 17,534 33,735 AFFILIATED
  • NASDAQ Stock Market

    NASDAQ Stock Market

    Nasdaq Stock Market Friday, December 28, 2018 Name Symbol Close 1st Constitution Bancorp FCCY 19.75 1st Source SRCE 40.25 2U TWOU 48.31 21st Century Fox Cl A FOXA 47.97 21st Century Fox Cl B FOX 47.62 21Vianet Group ADR VNET 8.63 51job ADR JOBS 61.7 111 ADR YI 6.05 360 Finance ADR QFIN 15.74 1347 Property Insurance Holdings PIH 4.05 1-800-FLOWERS.COM Cl A FLWS 11.92 AAON AAON 34.85 Abiomed ABMD 318.17 Acacia Communications ACIA 37.69 Acacia Research - Acacia ACTG 3 Technologies Acadia Healthcare ACHC 25.56 ACADIA Pharmaceuticals ACAD 15.65 Acceleron Pharma XLRN 44.13 Access National ANCX 21.31 Accuray ARAY 3.45 AcelRx Pharmaceuticals ACRX 2.34 Aceto ACET 0.82 Achaogen AKAO 1.31 Achillion Pharmaceuticals ACHN 1.48 AC Immune ACIU 9.78 ACI Worldwide ACIW 27.25 Aclaris Therapeutics ACRS 7.31 ACM Research Cl A ACMR 10.47 Acorda Therapeutics ACOR 14.98 Activision Blizzard ATVI 46.8 Adamas Pharmaceuticals ADMS 8.45 Adaptimmune Therapeutics ADR ADAP 5.15 Addus HomeCare ADUS 67.27 ADDvantage Technologies Group AEY 1.43 Adobe ADBE 223.13 Adtran ADTN 10.82 Aduro Biotech ADRO 2.65 Advanced Emissions Solutions ADES 10.07 Advanced Energy Industries AEIS 42.71 Advanced Micro Devices AMD 17.82 Advaxis ADXS 0.19 Adverum Biotechnologies ADVM 3.2 Aegion AEGN 16.24 Aeglea BioTherapeutics AGLE 7.67 Aemetis AMTX 0.57 Aerie Pharmaceuticals AERI 35.52 AeroVironment AVAV 67.57 Aevi Genomic Medicine GNMX 0.67 Affimed AFMD 3.11 Agile Therapeutics AGRX 0.61 Agilysys AGYS 14.59 Agios Pharmaceuticals AGIO 45.3 AGNC Investment AGNC 17.73 AgroFresh Solutions AGFS 3.85
  • DCAT MEMBER COMPANY MEETING LOCATOR V. 4

    DCAT MEMBER COMPANY MEETING LOCATOR V. 4

    DCAT MEMBER COMPANY MEETING LOCATOR v. 4 THE BENJAMIN Sancilio Pharmaceuticals Company, Inc. Sri Krishna Pharmaceuticals Ltd. Amino Chemicals Ltd. Zydus Pharmaceuticals (USA) Inc. Apogee Pharma, Inc. C2 PHARMA INTERCONTINENTAL BARCLAY Calyx Chemicals & Pharmaceuticals Ltd. AbbVie* ChemCon GmbH ACIC Pharmaceuticals Inc. Concord Biotech Limited Advitech SA Dipharma Francis Srl Amneal Pharmaceuticals LLC DSM Sinochem Pharmaceuticals ALP Pharm F.I.S. - Fabbrica Italiana Sintetici S.p.A. AMRI Jost Chemical Co. Asymchem Inc. Jubilant Pharma Capsugel, Now a Lonza Company* PharmSource, A GlobalData Company CBC AMERICAS Corp. PolyPeptide Group CellMark USA, LLC ROHNER Inc. Charioteer Pharmaceutical Co., Ltd., Zhejiang FIFTY NYC, A AFFINA HOTEL Chemical and Pharmaceutical Solutions Chiral Quest Corp. Chartwell Pharmaceuticals, LLC Croda, Inc. HOTEL 48LEX DFE Pharma AB BioTechnologies, Inc. DPL-US AiPing Pharmaceutical, Inc. EQ Esteve Almac Evonik Corporation Aptuit LLC FAREVA SA AZAD Fine Chemicals Ltd. Flavine North America, Inc. Cambridge Isotope Laboratories, Inc. Formosa Laboratories, Inc. CMC Biologics Grifols International S.A. Groupe Parima Hainan Poly Pharm. Co., Ltd. Navin Fluorine International Limited Harris Pharmaceutical Qualicaps, Inc. Helm AG RC2 Pharma Connect LLC Hetero USA, Inc. Recipharm Hikal, Ltd. Recro Gainesville LLC Interchem Corporation Reed-Lane, Inc. Inventia Healthcare PVT LTD Please note: Some DCAT member companies have requested not to be listed in the locator. (*) indicates member companies with Business Meeting Spaces in more than one hotel. INTERCONTINENTAL BARCLAY CONT'D PiSA BioPharm, Inc. SPI Pharma Inc. Johnson Matthey Tapemark Kingchem Life Science LLC Unither Pharmaceutical Legacy Pharmaceutical Packaging Uquifa S.A. Lonza AG* Neuland Laboratories Ltd. LOTTE NY PALACE Orion Group AbbVie* Par Pharmaceutical, Inc.
  • Eli Lilly and Company

    Eli Lilly and Company

    Merrimack College Merrimack ScholarWorks Honors Senior Capstone Projects Honors Program Spring 2021 Eli Lilly and Company Alyssa Ardai Follow this and additional works at: https://scholarworks.merrimack.edu/honors_capstones Part of the Business Commons Ardai 1 Written Assignment #4 Eli Lilly and Company Alyssa Ardai Bus 4402W: Strategic Analysis and Decision Making Professor Herrmann April 30, 2021 Ardai 2 Abstract Eli Lilly and Company is a pharmaceutical company that has the goal of creating new products. Eli Lilly’s products are seen in hospitals and pharmacies around the US, with the hopes of growing internationally. By having a large number of drugs in their pipeline, they can be a key player in improving multiple types of illnesses as well as help aid the aging population. The healthcare sector is always one that is high-performing. Ardai 3 Eli Lilly and Company is positioned as a pharmaceutical company, with the goal of creating high-quality medicine for every need or to take a preexisting medicine and make it better. For the past 140 years, they have been creating medicine for various causes, but are now focusing their efforts on antibody treatments for the COVID-19 pandemic, as well as different cancers and autoimmune diseases. Everything that the company does should follow its core values: integrity, excellence, and respect for people (Eli Lilly and Company - A). Eli Lilly is found in the US, Japan, Europe, and hopes to expand to the rest of the world soon. They are broken down into Endocrinology, Oncology, Immunology, Neuroscience, & Other. The company has increased revenues from $23,832.8 - $25,925.3, a consistent tax rate of 15%, expenses increasing $300k a year, accounts receivable, or a/r, decreasing as they pay less in patents and drugs go generic, consistent inventory of $120k - $140k, showing they do not keep a lot on hand, a weighted average cost of capital, or WACC, of 5.9% showing it does not hold a lot of debt, and a long term growth rate of 2.3%, showing a healthy but stable growth (Bloomberg LP, CapitalIQ 2021).
  • BTG INTERNATIONAL LIMITED V. AMNEAL PHARMACEUTICALS LLC

    BTG INTERNATIONAL LIMITED V. AMNEAL PHARMACEUTICALS LLC

    United States Court of Appeals for the Federal Circuit ______________________ BTG INTERNATIONAL LIMITED, JANSSEN BIOTECH, INC., JANSSEN ONCOLOGY, INC., JANSSEN RESEARCH & DEVELOPMENT, LLC, Plaintiffs-Appellants v. AMNEAL PHARMACEUTICALS LLC, AMNEAL PHARMACEUTICALS OF NEW YORK, LLC, DR. REDDY'S LABORATORIES, INC., DR. REDDY'S LABORATORIES, LTD., WOCKHARDT BIO AG, WOCKHARDT USA LLC, WOCKHARDT LTD., MYLAN PHARMACEUTICALS INC., MYLAN INC., WEST-WARD PHARMACEUTICALS CORP., NKA HIKMA PHARMACEUTICALS USA INC., HIKMA PHARMACEUTICALS LLC, TEVA PHARMACEUTICALS USA, INC., Defendants-Appellees PAR PHARMACEUTICAL, INC., PAR PHARMACEUTICAL COMPANIES, INC., RISING PHARMACEUTICALS, INC., Defendants ______________________ 2019-1147 ______________________ Appeal from the United States District Court for the District of New Jersey in Nos. 2:15-cv-05909-KM-JBC, 2:16-cv-02449-KM-JBC, 2:17-cv-06435-KM-JBC, Judge Kevin McNulty. 2 BTG INTERNATIONAL LIMITED v. AMNEAL PHARMACEUTICALS LLC - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - BTG INTERNATIONAL LIMITED, JANSSEN BIOTECH, INC., JANSSEN ONCOLOGY, INC., JANSSEN RESEARCH & DEVELOPMENT, LLC, Plaintiffs-Appellants v. AMERIGEN PHARMACEUTICALS, INC., AMERIGEN PHARMACEUTICALS LIMITED, Defendants-Appellees ______________________ 2019-1148 ______________________ Appeal from the United States District Court for the District of New Jersey in No. 2:16-cv-02449-KM-JBC, Judge Kevin McNulty. - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - JANSSEN
  • Advances in Management of Diabetic Retinopathy Featuring the P

    Advances in Management of Diabetic Retinopathy Featuring the P

    Advances in Management of Diabetic Retinopathy featuring the P. Kenneth Nase Memorial Lecture (05/22/21 @ 8 a.m. ET) Saturday, May 22, 2021 Online Name of commercial interest/Nature Name of individual Individual's role in activity of relationship Grant / Research Support-Apellis Pharmaceuticals|Grant / Research Support-Genentech|Consultant / Independent Contractor-Apellis Allen Chiang, MD Faculty Pharmaceuticals|Grant / Research Support-Regeneron|Consultant / Independent Contractor-Orbit Biomedical - 03/19/2021 Consultant / Independent Contractor- Michael N Cohen, MD Faculty Allergan|Consultant / Independent Contractor-Keeler, Inc. - 05/04/2021 Consultant / Independent Contractor- Deciphera|Consultant / Independent Contractor-Bausch & Lomb|Consultant / Independent Contractor-Johnson and Johnson|Consultant / Independent Sunir J. Garg, MD Faculty Contractor-Allergan|Grant / Research Support-Regeneron|Grant / Research Support-Apellis|Grant / Research Support-Boehringer Ingelheim - 02/24/2021 Omesh Gupta, MD Faculty Nothing to disclose - 03/21/2021 Advisor / Board Member-IVERIC Bio|Grant / Research Support-IVERIC Bio|Consultant / Independent Contractor-Gyroscope Jason Hsu, MD Faculty Therapeutics|Consultant / Independent Contractor-OccuRx|Grant / Research Support-Genentech|Grant / Research Support-Aldeyra Therapeutics - 03/20/2021 Consultant / Independent Contractor- Allergan|Consultant / Independent M. Ali Khan, MD Faculty Contractor-Apellis Pharmaceuticals|Consultant / Independent Contractor- Genentech|Grant / Research Support- Regeneron
  • The Year of Investment, Innovation and Implementation

    The Year of Investment, Innovation and Implementation

    2017 the year of investment, innovation and implementation 2017 annual report healthcare businesswomen’s association table of contents LETTER FROM CHAIR 1 INVESTMENT 2017 BY THE NUMBERS 2 MEMBERSHIP 2 CHAPTER BREAKDOWN 2 40 YEARS OF MILESTONES 2 MEMBER/VOLUNTEER SURVEY RESULTS 3 FINANCIALS 4 INNOVATION AND IMPLEMENTATION 2017 FLAGSHIP EVENTS 7 WOMAN OF THE YEAR 8 LUMINARIES 10 RISING STARS 11 ANNUAL CONFERENCE 13 ACE AWARDS 14 THE GENDER PARITY COLLABORATIVE CLICK HERE HBA “NOW” THE NEW OPERATING MODEL CLICK HERE IN APPRECIATION—WE COULDN’T DO IT WITHOUT YOU 2017 CORPORATE PARTNERS 15 2017 SPONSORS 16 2017 MEDIA PARTNERS 17 HBA ADVISORY BOARD 18 HBA BOARD OF DIRECTORS 19 LETTER FROM CEO LAURIE COOKE 20 HBA 2017 II annual report letter from the chair In my long career as a healthcare executive, I have seen firsthand the benefits of diversity in leadership time and again. From gender to ethnicity to age and other factors, the best engagement and the most powerful results always arise when there is a diversity of perspectives in the room. This is why I joined the HBA board. This year marks the 40th anniversary of the organization’s founding. And though I am a relatively new member, I quickly became a believer in the HBA’s rich history and deep commitment to both the advancement of women individually, and to the achievement of gender parity in healthcare overall. This is also why I am proud of the HBA’s aggressive—but achievable—strategic plan to move the needle on gender parity through partnership by 2020.